FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
ASLAN Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for ASLAN Pharmaceuticals Limited (ASLN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisASLN
ASLN
ASLAN Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASLN
Home🔹Stocks🔹ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN•NASDAQ

ASLAN Pharmaceuticals Limited

ASLN•NASDAQ
Market cap
$777.12M
Sentiment

Your view on ASLN

Mkt Cap
$777.12M
Sentiment
Your view
ASLN
ASLAN Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASLN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ASLAN Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Carl Alan Jason Morton Firth EMBA,
Headquarters
SG
Industry
Biotechnology
Sector
Healthcare
CEO
Carl Alan Jason Morton Firth EMBA,
Headquarters
SG
Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News